Eurofins BioPharma Product Testing (BPT) Italy has officially launched Viral Clearance Services at its Milan site, further expanding the Eurofins BPT network’s global footprint in viral safety services.
Since 2009, the Virus Testing Unit in Milan has supported biopharmaceutical companies with viral inactivation studies (e.g., low pH and solvent/detergent treatments) on their products. In response to the growing development of biologic drugs and increasing awareness of viral safety requirements, the expansion into viral removal studies represents a significant enhancement of our analytical capabilities. This milestone strengthens both Eurofins BPT’s global offering and its local presence in Europe.
What differentiates us is our flexible, client-focused approach—each study is tailored to meet the specific needs and expectations of our clients. Additionally, our reduced backlog allows for faster project initiation, offering a critical time advantage in development timelines.
Clients can choose between two service models:
- A standard full-service model, in which Eurofins BPT conducts the entire study, including technology transfer and scaled-down process execution with virus spiking and detection.
- A hybrid-service model, where clients access our virus testing facility and use our purification equipment (e.g., ÄKTA systems or filtration setups), while our expert Virology Team manages all virological operations, including spiking, sampling, and virus detection.
The Virus Testing Unit operates within a GLP-compliant testing facility, supported by a comprehensive viral library (over 40 strains, including XMuLV, PRV, MVM, and Reo-3), a 450 m² laboratory, an ÄKTA Pure 25 system, and all necessary equipment for viral clearance studies.
For further information and details please visit: www.eurofins.com/BPT